间质性肺疾病和继发性肺动脉高压

Slobodan Belić, N. Maric, Nataša Đurđević, Aleksandra Golubović, I. Milivojević, M. Geratović, N. Nikolić, Irina Čokrlić, M. Stjepanović
{"title":"间质性肺疾病和继发性肺动脉高压","authors":"Slobodan Belić, N. Maric, Nataša Đurđević, Aleksandra Golubović, I. Milivojević, M. Geratović, N. Nikolić, Irina Čokrlić, M. Stjepanović","doi":"10.5937/smclk4-41136","DOIUrl":null,"url":null,"abstract":"Interstitial lung disease alone can have a poor prognosis, and when associated with pulmonary hypertension there is a significant reduction in survival rates. Since the incidence of pulmonary hypertension in patients with interstitial lung diseases is very high and the symptoms are similar and often unrecognized, our aim is to point out the significance of both coexisting diseases and to prompt clinicians to suspect pulmonary hypertension. Through a brief review of the pathohistological changes, diagnostic methods, and the clinical presentation of these diseases, the similarities and differences that can help in the management of these patients, are shown. The latest treatment guidelines, with a special focus on the impact of antifibrotic treatment (nintedanib and pirfenidone) on pulmonary hypertension, are presented.","PeriodicalId":286220,"journal":{"name":"Srpski medicinski casopis Lekarske komore","volume":"24 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interstitial lung diseases and secondary pulmonary hypertension\",\"authors\":\"Slobodan Belić, N. Maric, Nataša Đurđević, Aleksandra Golubović, I. Milivojević, M. Geratović, N. Nikolić, Irina Čokrlić, M. Stjepanović\",\"doi\":\"10.5937/smclk4-41136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Interstitial lung disease alone can have a poor prognosis, and when associated with pulmonary hypertension there is a significant reduction in survival rates. Since the incidence of pulmonary hypertension in patients with interstitial lung diseases is very high and the symptoms are similar and often unrecognized, our aim is to point out the significance of both coexisting diseases and to prompt clinicians to suspect pulmonary hypertension. Through a brief review of the pathohistological changes, diagnostic methods, and the clinical presentation of these diseases, the similarities and differences that can help in the management of these patients, are shown. The latest treatment guidelines, with a special focus on the impact of antifibrotic treatment (nintedanib and pirfenidone) on pulmonary hypertension, are presented.\",\"PeriodicalId\":286220,\"journal\":{\"name\":\"Srpski medicinski casopis Lekarske komore\",\"volume\":\"24 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Srpski medicinski casopis Lekarske komore\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/smclk4-41136\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Srpski medicinski casopis Lekarske komore","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/smclk4-41136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

单独的间质性肺疾病可能预后不良,当合并肺动脉高压时,生存率显著降低。由于肺间质性疾病患者肺动脉高压的发生率非常高,且症状相似且常常不被认识,我们的目的是指出这两种疾病共存的意义,并提示临床医生怀疑肺动脉高压。通过对这些疾病的病理组织学变化,诊断方法和临床表现的简要回顾,显示了这些疾病的异同,可以帮助这些患者的管理。最新的治疗指南,特别关注抗纤维化治疗(尼达尼布和吡非尼酮)对肺动脉高压的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Interstitial lung diseases and secondary pulmonary hypertension
Interstitial lung disease alone can have a poor prognosis, and when associated with pulmonary hypertension there is a significant reduction in survival rates. Since the incidence of pulmonary hypertension in patients with interstitial lung diseases is very high and the symptoms are similar and often unrecognized, our aim is to point out the significance of both coexisting diseases and to prompt clinicians to suspect pulmonary hypertension. Through a brief review of the pathohistological changes, diagnostic methods, and the clinical presentation of these diseases, the similarities and differences that can help in the management of these patients, are shown. The latest treatment guidelines, with a special focus on the impact of antifibrotic treatment (nintedanib and pirfenidone) on pulmonary hypertension, are presented.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信